Silence picks up stake in US-based Arrowhead
The UK’s Silence Therapeutics has snapped up a stake in fellow RNA therapeutics group US biotech Arrowhead Pharmaceuticals for around £7.8 million, to expand its potential reach in the field.
Read More
Tag: RNA therapeutics
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
